The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 

Editor

Share

Personal info

View

Links

Table of contents

About

Terms

 

Alba Ariela Brandes

Department of Oncology

Azienda Ospedale-Universita

Padova

Italy

[email]@unipd.it

Name/email consistency: high

 
 
 
 
 
 
 

Affiliations

  • Department of Oncology, Azienda Ospedale-Universita, Padova, Italy. 2001 - 2005
  • Divisione di Oncologia-Direzione Azienda Ospedale-Universita, Via Giustiniani 2, 35100 Padova, Italy. 2001 - 2004
  • Department of Medical Oncology and Neurological Sciences of Azienda Ospedale-Università, Padua, Italy. 2003 - 2004
  • Medical Oncology Department, University Hospital, Via Gattamelata 64, 35100 Padova, Italy. 2004

References

  1. A multicenter retrospective study of chemotherapy for recurrent intracranial ependymal tumors in adults by the Gruppo Italiano Cooperativo di Neuro-Oncologia. Brandes, A.A., Cavallo, G., Reni, M., Tosoni, A., Nicolardi, L., Scopece, L., Franceschi, E., Sotti, G., Talacchi, A., Turazzi, S., Ermani, M. Cancer (2005) [Pubmed]
  2. First-line chemotherapy with cisplatin plus fractionated temozolomide in recurrent glioblastoma multiforme: a phase II study of the Gruppo Italiano Cooperativo di Neuro-Oncologia. Brandes, A.A., Basso, U., Reni, M., Vastola, F., Tosoni, A., Cavallo, G., Scopece, L., Ferreri, A.J., Panucci, M.G., Monfardini, S., Ermani, M. J. Clin. Oncol. (2004) [Pubmed]
  3. Review of the prognostic factors in medulloblastoma of children and adults. Brandes, A.A., Paris, M.K. Crit. Rev. Oncol. Hematol. (2004) [Pubmed]
  4. Efficacy and feasibility of standard procarbazine, lomustine, and vincristine chemotherapy in anaplastic oligodendroglioma and oligoastrocytoma recurrent after radiotherapy. A Phase II study. Brandes, A.A., Tosoni, A., Vastola, F., Pasetto, L.M., Coria, B., Danieli, D., Iuzzolino, P., Gardiman, M., Talacchi, A., Ermani, M. Cancer (2004) [Pubmed]
  5. How effective is BCNU in recurrent glioblastoma in the modern era? A phase II trial. Brandes, A.A., Tosoni, A., Amistà, P., Nicolardi, L., Grosso, D., Berti, F., Ermani, M. Neurology (2004) [Pubmed]
  6. Second-line chemotherapy with irinotecan plus carmustine in glioblastoma recurrent or progressive after first-line temozolomide chemotherapy: a phase II study of the Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO). Brandes, A.A., Tosoni, A., Basso, U., Reni, M., Valduga, F., Monfardini, S., Amistà, P., Nicolardi, L., Sotti, G., Ermani, M. J. Clin. Oncol. (2004) [Pubmed]
  7. A prospective study on glioblastoma in the elderly. Brandes, A.A., Vastola, F., Basso, U., Berti, F., Pinna, G., Rotilio, A., Gardiman, M., Scienza, R., Monfardini, S., Ermani, M. Cancer (2003) [Pubmed]
  8. The treatment of adults with medulloblastoma: a prospective study. Brandes, A.A., Ermani, M., Amista, P., Basso, U., Vastola, F., Gardiman, M., Iuzzolino, P., Turazzi, S., Rotilio, A., Volpin, L., Mazza, C., Sainati, L., Ammannati, F., Berti, F. Int. J. Radiat. Oncol. Biol. Phys. (2003) [Pubmed]
  9. Medulloblastomas: do molecular and biologic markers indicate different prognoses and treatments?. Brandes, A.A., Paris, M.K., Basso, U. Expert. Rev. Anticancer. Ther (2003) [Pubmed]
  10. Carboplatin and teniposide as third-line chemotherapy in patients with recurrent oligodendroglioma or oligoastrocytoma: a phase II study. Brandes, A.A., Basso, U., Vastola, F., Tosoni, A., Pasetto, L.M., Jirillo, A., Lonardi, S., Paris, M.K., Koussis, H., Monfardini, S., Ermani, M. Ann. Oncol. (2003) [Pubmed]
  11. A multidrug combination designed for reversing resistance to BCNU in glioblastoma multiforme. Brandes, A.A., Turazzi, S., Basso, U., Pasetto, L.M., Guglielmi, B., Volpin, L., Iuzzolino, P., Amistà, P., Pinna, G., Scienza, R., Ermani, M. Neurology (2002) [Pubmed]
  12. Temozolomide in patients with glioblastoma at second relapse after first line nitrosourea-procarbazine failure: a phase II study. Brandes, A.A., Ermani, M., Basso, U., Paris, M.K., Lumachi, F., Berti, F., Amistà, P., Gardiman, M., Iuzzolino, P., Turazzi, S., Monfardini, S. Oncology (2002) [Pubmed]
  13. Controversies in the therapy of low-grade glioma: when and how to treat. Brandes, A.A., Vastola, F., Basso, U. Expert. Rev. Anticancer. Ther (2002) [Pubmed]
  14. New strategy developments in brain tumor therapy. Brandes, A.A., Basso, U., Pasetto, L.M., Ermani, M. Curr. Pharm. Des. (2001) [Pubmed]
  15. Changing boundaries in the treatment of malignant gliomas. Brandes, A.A., Basso, U., Pasetto, L.M. Expert. Rev. Anticancer. Ther (2001) [Pubmed]
 
WikiGenes - Universities